Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer
Hamilton, E., Curigliano, G., Martín, M., Lerebours, F., Tsurutani, J., Savard, M., Jerzak, K. J., Hu, X., Pimentel, L. Martins de Aquino, O'Sullivan, CC, Tokunaga, Eriko , Huang, C., Jacot, W., Sohn, J., Silva, E. Cronemberger, Müller, Volkmar , Yang, S., Granata, G. , Shen, Qi , Santarpia, L., Diéras, V., Curigliano, Giuseppe , Tsurutani, Junji , Savard, M-F., Jerzak, Katarzyna J. , O’Sullivan, Ciara C. , Okines, Alicia , Jacot, William , Sohn, Joohyuk , Shen, Q., Santarpia, Libero , Dièras, Véronique

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS1-01-GS1-01

10.1158/1557-3265.sabcs25-gs1-01 Get It

Abstract Background: The current standard of care for first-line (1L) treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) consists of induction chemotherapy combined with trastuzumab (TRAS) and pertuzumab (PERT) followed by maintenance therapy with TRAS + PERT. Although this regimen has been associated with sustained disease control, most patients eventually experience disease progression. The HER2CLIMB-05(NCT05132582) study is investigating the efficacy and safety of adding tucatinib to TRAS + PERT as maintenance therapy in patients with HER2+ MBC after completion of 1L chemotherapy-based induction therapy. Methods: Patients with centrally confirmed HER2+MBC without evidence of progression after 1L induction therapy with 4 to 8cycles of a taxane combined with TRAS + PERT, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and no or asymptomatic brain metastases (BM) were enrolled in HER2CLIMB-05. Contrast-enhanced brain magnetic resonance imaging was performed at screening and regular intervals during the study. Patients were randomly assigned 1:1 to receive either tucatinib 300 mg or placebo twice daily, in combination with either TRAS (6 mg/kg IV or 600 mg SC) plus PERT (420 mg/kg IV) or a SC fixed-dose combination of TRAS, PERT, and hyaluronidase administered every 21 days. Endocrine therapy was permitted for patients with hormone receptor-positive tumors. The primary endpoint is investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints include overall survival (OS), PFS by blinded independent central review, investigator-assessed central nervous system (CNS)-PFS, and safety. Results: Between March 2022 and July 2024, 654 patients were randomly assigned to receive tucatinib (n = 326) or placebo (n = 328) with1L maintenance therapy. All patients were female (median age: 54 years [range, 24-83]);45.0% were White, 35.2% were Asian, 2.9% were Black/African American, and 19.3%were Hispanic/Latino(a)/Spanish origin. Most patients had ECOG PS of 0 (64.1%)and de novo metastatic disease (69.3%). At baseline, 12.4% of patients had presence or history of BM and 52.6% had hormone receptor-positive MBC. As of September5, 2025, PFS was statistically significantly improved with the addition of tucatinib versus placebo to 1L maintenance therapy (hazard ratio [HR] = 0.641 [95%confidence interval (CI), 0.514-0.799]; 2-sided P < 0.0001). All prespecified patient subgroups demonstrated a PFS benefit with tucatinib combination 1L maintenance therapy consistent with the overall population and regardless of presence or absence of BM at baseline or hormone-receptor status. OS is still immature (observed number of deaths = 51;tucatinib arm versus control arm HR = 0.539 [95% CI, 0.303-0.957; 2-sided P= 0.032]). In the safety analysis set, the most common treatment-emergent adverse events (TEAEs) in the tucatinib arm (n = 326) were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (alanine aminotransferase: 28.2%; aspartate aminotransferase:25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1% were, respectively, grade ≥ 3. In the tucatinib arm, 13.5% of patients discontinued tucatinib due to TEAEs. Conclusions: In the HER2CLIMB-05 trial, the addition of tucatinib to TRAS + PERT as 1L maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in PFS with a manageable safety profile in patients with HER2+ MBC. Citation Format: E. Hamilton, G. Curigliano, M. Martin, F. Lerebours, J. Tsurutani, M. Savard, K. Jerzak, X. Hu, L. Martins de Aquino Pimentel, C. O'Sullivan, E. Tokunaga, A. Okines, C. Huang, W. Jacot, J. Sohn, E. Cronemberger Silva, V. Mueller, S. Yang, G. Granata, Q. Shen, L. Santarpia, V. Dieras Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS1-01.
Accurate strand-specific long-read transcript isoform discovery and quantification at bulk, single-cell, and single-nucleus resolution
Yu, Houlin , Georgescu, Christophe, Khorgade, Akanksha , Al-Eryani, Ghamdan, Bartlett, Daniel A. , Brookhart, Allison, Kockan, Can, Shin, Asa, White, Emily, Reed, Xylena, Hu, Fangle, Bromberek, Sarah, Ndayambaje, Sandra, Aryal, Sandeep , Dickson, Dennis W, Lagier-Tourenne, Clotilde, Ward, Michael, Popic, Victoria , Haas, Brian J. , AlKhafaji, Aziz M, Ward, Michael E. , Dickson, Dennis W , Ward, Michael E , Blainey, Paul C , Georgescu, C , Al‐Eryani, Ghamdan , Koçkan, Can , Webber, James T. , Shin, Asa , Reed, Xylena , Prudencio, Mercedes , Lagier‐Tourenne, Clotilde , Al’Khafaji, Aziz M.

Mayo Clinic

No container title available | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.12.705617 | PMID 41726986 Get It

Abstract Recent advances in long-read transcriptome sequencing enable high-throughput profiling of full-length RNA isoforms in bulk, single-cell, and single-nucleus samples. However, long-read datasets typically contain a mixture of complete and partial transcripts, leading to pervasive ambiguity in read-to-isoform assignment and complicating accurate isoform identification and quantification, particularly in the absence of reliable reference annotations. These challenges are further amplified in single-cell and single-nucleus samples, where coverage is sparse and transcriptional heterogeneity is high. Here, we present the Long Read Alignment Assembler (LRAA), a unified and versatile computational framework for isoform identification and quantification from long-read RNA sequencing data across bulk, single-cell, and single-nucleus transcriptomic samples. LRAA combines splice-graph based structural modeling with expectation maximization based optimization to probabilistically resolve ambiguous read assignments and improve isoform abundance estimation. The framework supports quantification-only, reference-guided, and fully reference-free (de novo) modes of analysis within a single methodological paradigm. We benchmarked LRAA using both simulated and genuine long-read datasets spanning sequencing standards and whole transcriptomes. Central to this evaluation is a novel benchmarking strategy based on Multiplexed Overexpression of Regulatory Factors (MORFs), which provides biologically expressed, barcoded isoforms with unambiguous read-level ground truth. Across all benchmarks, including MORFs, synthetic spike-ins, and whole-transcriptome datasets, LRAA consistently outperformed state-of-the-art methods in isoform identification accuracy, sensitivity, and expression quantification. Finally, we demonstrate the biological utility of LRAA by resolving cell-type-specific isoform usage across peripheral blood immune cell populations and by detecting a pathogenic cryptic isoform of STMN2 with associated transcriptional changes in single-nucleus RNA-seq data from frontal cortex tissue of an individual with frontotemporal dementia (FTD). Together, these results establish LRAA as a robust and general solution for resolving transcript diversity in complex biological systems, from development to disease.
“Nobody Told Me”: A Qualitative Study of Sexual and Reproductive Concerns After Treatment for Early-Onset Colorectal Cancer
Bradley, Sarah E., Vitous, C. Ann, Marzoughi, Maedeh , Ashmead-Meers, Claire, Norton, Tabitha E, Boyce-Suwanabol, Jordan, Suwanabol, Pasithorn A. , Ashmead-Meers, Claire C, Savitch, Samantha L. , Bradley, Sarah E. , Vitous, C. Ann , Ashmead-Meers, Claire , Jacobson, Clare E. , Norton, Tabitha E

Mayo Clinic

Diseases of the Colon & Rectum | February 12, 2026 | Volume: 69 | Issue: 6 | Pages: 1732-1740

10.1097/dcr.0000000000004181 | PMID 41676985 Get It

BACKGROUND: The incidence of early-onset colorectal cancer is rising, yet survivorship care guidelines rarely address concerns unique to younger adults. Although treatment for colorectal cancer can have devastating consequences related to sexual function and fertility, these issues remain underrecognized and seldom addressed. OBJECTIVE: To better understand the impact of colorectal cancer diagnosis and treatment on sexual and reproductive health. DESIGN: Qualitative study of patients with early-onset colorectal cancer. SETTINGS: Semi-structured one-to-one Zoom interviews of patients recruited through convenience sampling from 7 academic institutions. PATIENTS: Sixty-three individuals diagnosed with colorectal cancer aged 50 years or younger were interviewed between March 2021 and August 2024. MAIN OUTCOME MEASURES: Patient perspectives regarding the sexual and reproductive health impacts of colorectal cancer diagnosis and treatment. Data were analyzed iteratively using directed and conventional qualitative content analysis. RESULTS: Participants discussed sexual and reproductive health side effects resulting from surgery, chemotherapy, and radiation. These side effects ranged in severity, with some experiencing almost none and others facing significant issues. They identified several domains, including surgical and treatment side effects, psychological impacts, effects on relationships, and unmet needs. Subdomains included sexual health, reproductive health, emotional distress, body image, communication challenges, impacts on dating, informational needs, financial support, and consultations. LIMITATIONS: Participants were recruited from academic medical centers only, and as such, responses may not reflect the experiences of those cared for in nonacademic settings. CONCLUSIONS: Sexual and reproductive health are critical but often overlooked concerns among younger patients with CRC, with significant impacts on physical functioning, partner relationships, and psychological well-being. Current survivorship guidelines fail to adequately address these needs. Our findings highlight the importance of pretreatment counseling and fertility preservation as well as the need for ongoing mental health support during and after cancer treatment. See Video Abstract . «NADIE ME LO DIJO»: ESTUDIO CUALITATIVO SOBRE LAS PREOCUPACIONES SEXUALES Y REPRODUCTIVAS TRAS EL TRATAMIENTO DEL CÁNCER COLORRECTAL DE APARICIÓN TEMPRANA ANTECEDENTES: La incidencia del cáncer colorrectal de aparición temprana está aumentando, pero las directrices sobre cuidados para supervivientes rara vez abordan las preocupaciones específicas de los adultos jóvenes. Aunque el tratamiento del cáncer colorrectal puede tener consecuencias devastadoras para la función sexual y la fertilidad, estas cuestiones siguen sin reconocerse lo suficiente y rara vez se abordan. OBJETIVO: Comprender mejor el impacto del diagnóstico y el tratamiento del cáncer colorrectal en la salud sexual y reproductiva. DISEÑO: Estudio cualitativo de pacientes con cáncer colorrectal de aparición temprana. ENTORNO: Entrevistas individuales semiestructuradas por Zoom a pacientes reclutados mediante muestreo por conveniencia en siete instituciones académicas. PACIENTES: Se entrevistó a 63 personas diagnosticadas con cáncer colorrectal antes de los 50 años entre marzo de 2021 y agosto de 2024. PRINCIPALES MEDIDAS DE RESULTADOS: Perspectivas de los pacientes sobre el impacto del diagnóstico y el tratamiento del cáncer colorrectal en la salud sexual y reproductiva. Los datos se analizaron de forma iterativa mediante un análisis de contenido cualitativo dirigido y convencional. RESULTADOS: Los participantes discutieron los efectos secundarios en la salud sexual y reproductiva derivados de la cirugía, la quimioterapia y la radiación. Estos efectos secundarios variaban en gravedad, ya que algunos no experimentaban casi ninguno y otros se enfrentaban a problemas importantes. Identificaron varios ámbitos, entre ellos los efectos secundarios de la cirugía y el tratamiento, las repercusiones psicológicas, los efectos en las relaciones y las necesidades no satisfechas. Los subámbitos incluían la salud sexual, la salud reproductiva, el malestar emocional, la imagen corporal, los problemas de comunicación, las repercusiones en las relaciones sentimentales, las necesidades de información, el apoyo financiero y las consultas. LIMITACIONES: Los participantes fueron reclutados únicamente en centros médicos académicos, por lo que es posible que las respuestas no reflejen las experiencias de las personas atendidas en entornos no académicos. CONCLUSIONES: La salud sexual y reproductiva son cuestiones fundamentales, pero a menudo se pasan por alto entre los pacientes jóvenes con CCR, con repercusiones significativas en el funcionamiento físico, las relaciones de pareja y el bienestar psicológico. Las directrices actuales para la supervivencia no abordan adecuadamente estas necesidades. Nuestros hallazgos ponen de relieve la importancia del asesoramiento previo al tratamiento y la preservación de la fertilidad, así como la necesidad de un apoyo continuo a la salud mental durante y después del tratamiento del cáncer. (AI-generated translation )
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
Beck, David B. , Heiblig, Maël , Savic, S., Ferrada, Marcela A. , Mekinian, Arsène, Chowdhury, Onima , Hammond, Danielle E., Weeks, Lachelle D., Gurnari, Carmelo , Kirino, Yohei , Georgin-Lavialle, Sophie, Buckley, Sarah A., Garcha, Raman, Harder, Bryan G., Harder, Bryan , Weeks, Lachelle D. , Mékinian, A. , Savic, Sinisa , Hammond, Danielle , Georgin‐Lavialle, Sophie , Savic, Sinisa , Mékinian, Arsène , Hammond, Danielle , Weeks, Lachelle Dawn , Georgin-Lavialle, Sophie , Buckley, Sarah A , Harder, Bryan G , Koster, Matthew J , Gurnari, Carmelo , Kirino, Yohei , Heiblig, Mael , Ferrada, Marcela A , Koster, Matthew J.

Mayo Clinic

Journal of Clinical Medicine | February 11, 2026 | Volume: 15 | Issue: 4 | Pages: 1426

10.3390/jcm15041426 | PMID 41753113 Get It

VEXAS (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Most patients require chronic use of moderate-to-high doses of glucocorticoids (GCs) to maintain disease control. Data on GC-sparing therapies is limited, and there have been no prospective pharmacotherapeutic trials in VEXAS syndrome published to date. Pacritinib, an oral inhibitor of IRAK1, JAK2, and ACVR1, has emerged as a promising therapeutic option for VEXAS syndrome. The PAXIS trial is the first prospective, randomized pharmacotherapeutic study conducted in this rare and severe disease. Utilizing a novel study design and disease-specific endpoints, the trial will evaluate the efficacy and safety of two dose levels of pacritinib compared with placebo in patients with VEXAS syndrome (NCT06782373, EUCTR: 2024-516347-41-00).
Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus
Gross, Seth, Shaukat, Aasma, Afzali, A, Ahn, Joseph C., Bajaj, Jasmohan S. , Barkin, Jodie A. , Bilal, Mohammad, Chawla, Saurabh , Coelho-Prabhu, Nayantara, Enslin, Sarah , Feld, Andrew, Gagneja, Harish K., Hass, David J., Horst, Sara N., Jones, Patricia D. , Kushnir, Vladimir M., Leggett, Cadman L. , Leung, Galen G., Mascarenhas, M., Parasa, Sravanthi, Parsa, Nasim , Schairer, Jason N., Spiegel, Brennan, Suthrum, Praveen, Thomas, Sapna, Phillips, Meridith E., Coelho–Prabhu, Nayantara , Spiegel, Brennan , Afzali, Anita , Ahn, Joseph , Bilal, Mohammad , Afzali, Anita , Ahn, Joseph C , Coelho-Prabhu, Nayantara , Enslin, Sarah M , Hernandez-Barco, Yasmin G , Horst, Sara , Jacobson, Brian C , Jones, Patricia D , Kaul, Vivek , Leggett, Cadman L , Leung, Galen , Mascarenhas, Miguel , Parasa, Sravanthi , Shah, Eric D , Simonetto, Douglas A , Stidham, Ryan W , Suthrum, Praveen , Thomas, Sapna , Phillips, Meridith E , Bilal, Mohammad , Spiegel, Brennan , Shaukat, Aasma , Afzali, Arya , Feld, Andrew D., Hernandez‐Barco, Yasmin G. , Horst, Sara , Kushnir, Vladimir , Parasa, Sravanthi , Schairer, Jason, Shah, Eric D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 1017-1024

10.14309/ajg.0000000000003944 | PMID 41665234 Get It

INTRODUCTION: The American College of Gastroenterology assembled a multidisciplinary task force to evaluate the current state and future direction of artificial intelligence (AI) in gastroenterology, hepatology, and endoscopy leading to the development of consensus-based recommendations for responsible AI integration in clinical practice. METHODS: A total of 32 subject-matter experts and 12 industry partners, representing diverse practice settings and expertise, conducted subgroup literature reviews across 5 key areas (endoscopy, practice management clinical applications, training and education, inflammatory bowel disease and liver disease, ethics and equity). Draft statements were developed and rated on a 5-point Likert scale using a modified Delphi process. A consensus was set at ≥70% combined agreement. Nonconsensus items were revised and revoted electronically. RESULTS: A total of 43 statements, 40 (93%) reached consensus in round 1 and the remaining 3 achieved consensus after round 2. Evidence supports computer-aided detection improving adenoma detection rate and miss rate in controlled studies, with mixed real-world impact and insufficient long-term outcomes (e.g., interval colon cancer rate). Recommendations emphasize thorough validation and reduction of bias by heterogeneous Data sets. Outside endoscopy, ambient AI scribes, natural language processing (NLP)-enabled coding, workflow optimization, and previous authorization support show potential. Training recommendations endorse a structured AI curriculum while preserving independent procedural competence to avoid deskilling. In inflammatory bowel disease and hepatology, AI could help improve diagnostic accuracy, help predict risk of disease progression, and help guide therapy. Equity, governance, and reimbursement statements call for chain-of-custody data protections, specialty-society oversight, and payment models that reward quality and cost reduction. DISCUSSION: This consensus outlines how AI can augment rather than replace clinical expertise while promoting safety, transparency, interoperability, and equity. Priorities include pragmatic and prospective trials, multi-institutional data-sharing consortia, bias mitigation, and workforce training to enable trustworthy and clinically impactful AI adoption in gastroenterology, liver, and endoscopy care.
Colon-Pilot: A Generative AI Tool for Automated Colonoscopy Surveillance Recommendations and 2024 ACG/ASGE Quality Benchmarking
Garg, Sushil Kumar , Mau, Brayden , Hubers, Jeffery , Arce, Victor, Hooper, Nicole, Lindquist, Jennifer, Harper, Sarah B. , Thayer, Ann B., Mukherjee, Piyush, Loufek, Brenna, Melnick, Joe , Rost, Lauren, Robbins, Steven A. , Chaudhary, Rajeev, Harper, Sarah B , Loufek, Brenna T , Rost, Lauren M , Gomes, Rahul , Chaudhary, Rajeev , Hubers, Jeffrey , Arce, Victor, Mukherjee, Piyush, Rost, Lauren M. , Gomes, Rahul

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 964-973

10.14309/ajg.0000000000003946 | PMID 41665228 Get It

INTRODUCTION: High-quality colonoscopy requires accurate risk stratification for surveillance per the 2020 US Multi-Society Task Force guidelines and adherence to 2024 American College of Gastroenterology/American Society for Gastrointestinal Endoscopy quality benchmarks. Both are operationally challenging in clinical practice. We developed and validated Colon-Pilot, a large language model—powered clinical decision support system using GPT-4o to automate and standardize both functions. METHODS: The system was evaluated in 2 operational modes: (i) a human-in-the-loop clinical decision support validation of surveillance recommendations for 596 colonoscopies, comparing concordance with 2020 US Multi-Society Task Force guidelines against expert consensus, and (ii) an automated administrative audit applying Colon-Pilot to 42,632 colonoscopies across the Mayo Clinic Health System to calculate 2024 American College of Gastroenterology/American Society for Gastrointestinal Endoscopy priority quality indicators. Recommendations were autogenerated unless predefined safety criteria triggered manual review. RESULTS: Colon-Pilot issued recommendations for 522 of 596 cases (87.6%) and flagged 12.4% for manual review. For automated cases, guideline-concordant accuracy was 97.5% (Cohen κ = 0.970) versus 69.7% (κ = 0.781) for original endoscopist recommendations. Discordant artificial intelligence (AI) cases (n = 13) most often recommended longer-than-appropriate intervals (62%). Applied to the enterprise data set, Colon-Pilot calculated performance exceeding 2024 targets: adenoma detection rate 49.8% (≥35%), sessile serrated lesion detection rate 17.7% (≥6%), bowel preparation adequacy 91.8% (≥90%), and cecal intubation rate 97.4% (≥95%). DISCUSSION: Colon-Pilot demonstrated high fidelity in applying surveillance guidelines and automated quality benchmarking, outperforming unassisted endoscopists in guideline adherence. By combining safety protocols with large-scale automated reporting, it offers a scalable solution for improving both efficiency and quality in colorectal cancer prevention.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026
Cheng, Heather H., Goggins, Michael, Yurgelun, Matthew B. , Karlan, Beth Y., Norquist, Barbara S., Daly, MB, Pal, Tuya, AlHilli, Zahraa, Arun, Banu , Churpek, Jane, Colonna, Sarah, Domchek, Susan M., Escobar, Mauricio R., Friedman, S, Hagemann, Andrea, Hendrix, Ashley, Huo, Dezheng, Hutton, Mollie L., Kassem, Nawal , Kurian, Allison W., Laronga, Christine , Mak, Julie S, McDonnell, Kevin, Mersch, Jacqueline, Offit, Kenneth, Plichta, Jennifer K. , Rash, Dominique , Reiser, Gwen , Senter-Jamieson, Leigha, Shannon, K. McWeeney, Welborn, Jeanna, Wick, Myra , Wood, Marie , Darlow, Susan, Diwan, Zeenat, Dwyer, Mary, Churpek, Jane E. , Kurian, Allison W. , Kurian, Allison W , Plichta, Jennifer K , Churpek, Jane E , Churpek, Jane , Giri, Veda N. , Goggins, Michael, Karlan, Beth Y , Norquist, Barbara, Pal, Tuya , Al‐Hilli, Zahraa , Arun, Banu , Colonna, Sarah V. , Domchek, Susan M. , Fejerman, Laura , Hagemann, Andrea, Huo, Dezheng , Khan, Seema A. , Mak, Julie , Maxwell, Kara N. , McDonnell, Kevin , Merajver, Sofía D. , Mersch, Jacqueline A, Offit, Kenneth , Darlow, Susan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 2-10

10.6004/jnccn.2026.0007 | PMID 41671423 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Srinagesh, Hrishikesh K. , Zhang, Amy, Grunwald, Michael R, Connor, Matthew P, Kota, Vamsi, Boccucci, Jacob , Ulrickson, M., Pradeep, Roshini , Hill, L, Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Sandhu, Karamjeet , Gordillo, Christian , Chen, Evan C., Lin, Chenyu, Kopmar, Noam E. , Majhail, Navneet S. , Lee, C F, Bobillo, Silvina Odstrcil, Park, Jae H, Valtis, Yannis K. , Solh, Melhem M, Guzowski, Caitlin, Vasu, Sumithira, Tan, Virginia, McCauley, Ross , Sasine, Joshua , Tang, Kevin, Kk, Miller, Sutherland, Katherine C. , Mohty, Razan , Jamy, Omer , Hoeg, Rasmus T., Logan, Aaron, Stock, Wendy A, Schwartz, Marc S., Byrd, Kenneth, Bachanova, Veronika, Tracy, Sean , Yaghmour, George , Gatell, Vivian Irizarry , Jackson, Clayton, Dholaria, Bhagirathbhai, O'Dwyer, Kristen M, Moore, Jozal , Aldoss, Ibrahim, Shah, B. D., Oliai, Caspian , Muffly, Lori, Grunwald, Michael R. , Kota, Vamsi , Bachanová, Veronika , Muffly, Lori , Hill, LaQuisa C. , Zhang, Amy , Connor, Matthew P. , Zhang, Amy , Grunwald, Michael , Connor, Matthew , Kota, Vamsi , Ulrickson, Matthew , Pradeep, Roshini , Hill, LaQuisa C , Advani, Anjali S , Reshef, Ran , Luskin, Marlise R , Chen, Evan , Lin, Chenyu , Cassaday, Ryan D , Kopmar, Noam E , Majhail, Navneet S , Battiwalla, Minoo , Strickland, Stephen Anthony , Lee, Catherine J , Odstrcil Bobillo, Silvina , Hilal, Talal , Faramand, Rawan , Leonard, Jessica T , Wang, Eunice S. , Sasine, Joshua , Sutherland, Katherine , Daunov, Michael , Jamy, Omer , Dykes, Kaitlyn C , Logan, Aaron C , Othman, Tamer , Stock, Wendy , Yalniz, Fevzi , Bachanova, Veronika , Irizarry Gatell, Vivian M , Oluwole, Olalekan O , Dholaria, Bhagirathbhai R , O'Dwyer, Kristin , Moore, Jozal , Roloff, Gregory W , Frey, Noelle V , Shah, Bijal , Oliai, Caspian H , Muffly, Lori , Gupta, Vishal , Ulrickson, Matthew L. , Tsai, Stephanie, Advani, Anjali S. , Reshef, Ran , Lin, Chenyu , Cassaday, Ryan D. , Battiwalla, Minoo , Bobillo, María Silvina Odstrcil , Hilal, Talal , Park, Jae H. , Faramand, Rawan , Solh, Melhem , Vasu, Sumithira , Daunov, Michael , Kumaran, Muthu Sendhil , Hoeg, Rasmus T. , Dykes, Kaitlyn C. , Othman, Tamer , Stock, Wendy , Byrd, Kenneth, Yalniz, Fevzi , Jackson, Clayton W., Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , Roloff, Gregory W. , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood | February 5, 2026 | Volume: 147 | Issue: 17 | Pages: 2011-2017

10.1182/blood.2025031734 | PMID 41643192 Get It

Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.